Compare ALTO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTO | DCTH |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.7M | 372.5M |
| IPO Year | 2005 | 2015 |
| Metric | ALTO | DCTH |
|---|---|---|
| Price | $5.18 | $12.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | ★ 2.6M | 444.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | 107.53 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $917,927,000.00 | N/A |
| Revenue This Year | $6.66 | $24.54 |
| Revenue Next Year | $0.43 | $33.15 |
| P/E Ratio | $103.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $8.12 |
| 52 Week High | $6.11 | $13.74 |
| Indicator | ALTO | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 54.55 |
| Support Level | $4.27 | $10.10 |
| Resistance Level | $6.02 | $13.74 |
| Average True Range (ATR) | 0.39 | 0.54 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 19.83 | 40.13 |
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.